DK0573604T3 - Fremgangsmåde til behandling af osteoporosis - Google Patents

Fremgangsmåde til behandling af osteoporosis

Info

Publication number
DK0573604T3
DK0573604T3 DK92908494.5T DK92908494T DK0573604T3 DK 0573604 T3 DK0573604 T3 DK 0573604T3 DK 92908494 T DK92908494 T DK 92908494T DK 0573604 T3 DK0573604 T3 DK 0573604T3
Authority
DK
Denmark
Prior art keywords
treatment
subject
treating osteoporosis
phosphonate
bone
Prior art date
Application number
DK92908494.5T
Other languages
English (en)
Inventor
Jocelyn Elaine Mcosker
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Application granted granted Critical
Publication of DK0573604T3 publication Critical patent/DK0573604T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Removal Of Specific Substances (AREA)
DK92908494.5T 1991-02-26 1992-01-31 Fremgangsmåde til behandling af osteoporosis DK0573604T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66177791A 1991-02-26 1991-02-26

Publications (1)

Publication Number Publication Date
DK0573604T3 true DK0573604T3 (da) 1995-05-29

Family

ID=24655074

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92908494.5T DK0573604T3 (da) 1991-02-26 1992-01-31 Fremgangsmåde til behandling af osteoporosis

Country Status (18)

Country Link
US (1) US6329354B1 (da)
EP (1) EP0573604B1 (da)
JP (1) JP3727332B2 (da)
KR (1) KR100240358B1 (da)
AT (1) ATE119777T1 (da)
AU (1) AU664368B2 (da)
CA (1) CA2101275C (da)
CZ (1) CZ282609B6 (da)
DE (1) DE69201725T2 (da)
DK (1) DK0573604T3 (da)
ES (1) ES2069424T3 (da)
HU (1) HU215124B (da)
IE (1) IE65963B1 (da)
NO (1) NO305581B1 (da)
NZ (1) NZ241717A (da)
RU (1) RU2113848C1 (da)
SK (1) SK90093A3 (da)
WO (1) WO1992014474A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE172118T1 (de) * 1992-03-21 1998-10-15 Entec Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose
WO1994009017A1 (en) * 1992-10-09 1994-04-28 The Upjohn Company Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
EP0675723A4 (en) * 1992-12-23 1998-08-05 Merck & Co Inc BIPHOSPHONATE / ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
CZ287984B6 (cs) * 1993-05-15 2001-03-14 Roche Diagnostics Gmbh Tableta se zlepšenou biodostupností účinné látky, kyseliny klodronové, a způsob její výroby
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
AR000555A1 (es) * 1994-12-28 1997-07-10 Gador Sa Uso de composiciones anabolicas para la masa osea en base a cantidades efectivas no toxicas del ácido Ä3-(n,n-dimetilamino)-1-hidroxipropilidenoÜbisfosfonico o la sal monosodica u otra sal farmacéuticamente aceptable del mismo
DE19635883A1 (de) * 1996-09-04 1998-03-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
WO1998023274A1 (en) * 1996-11-25 1998-06-04 Merck & Co., Inc. Androgenic and bisphosphonic agents coadministered to treat diseases
US6692763B1 (en) * 1998-11-19 2004-02-17 The Regents Of The University Of California Methods for treating postmenopausal women using ultra-low doses of estrogen
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
EP1057488A4 (en) * 1998-12-25 2003-10-22 Toray Industries INTERLEUKIN-6 PRODUCTION INHIBITORS
US6339078B1 (en) 1999-07-20 2002-01-15 University Of Florida Research Foundation, Inc. Methods of prevention and treatment of ischemic damage
US6326365B1 (en) 1999-07-20 2001-12-04 Apollo Biopharmaceutics, Inc. Methods of prevention and treatment of ischemic damage
US7335650B2 (en) 2000-01-14 2008-02-26 Sterix Limited Composition
US6653298B2 (en) 2000-01-14 2003-11-25 Sterix Limited Composition
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
ES2386851T3 (es) * 2007-11-30 2012-09-03 Novartis Ag Alquil (C2-C5)-imidazol-bisfosfonatos
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
PT2459176T (pt) 2009-07-31 2017-12-11 Gruenenthal Gmbh Método de cristalização e biodisponibilidade
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553314A (en) 1968-12-23 1971-01-05 Procter & Gamble Oral compositions for calculus retardation
US3683080A (en) 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
EP0088462A3 (en) * 1982-03-01 1984-06-06 The Procter & Gamble Company Anti-inflammatory and rheumatic composition containing organophosphonate and steroid
DE3583887D1 (de) * 1984-04-30 1991-10-02 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.
US4761406A (en) 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
IL86951A (en) 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
ATE119777T1 (de) 1995-04-15
IE920584A1 (en) 1992-08-26
RU2113848C1 (ru) 1998-06-27
SK90093A3 (en) 1994-09-07
HU9302407D0 (en) 1993-11-29
EP0573604A1 (en) 1993-12-15
CZ175593A3 (en) 1994-04-13
JPH06505501A (ja) 1994-06-23
EP0573604B1 (en) 1995-03-15
JP3727332B2 (ja) 2005-12-14
HU215124B (hu) 1998-09-28
WO1992014474A1 (en) 1992-09-03
HUT66429A (en) 1994-11-28
KR100240358B1 (ko) 2000-02-01
CA2101275A1 (en) 1992-08-27
ES2069424T3 (es) 1995-05-01
DE69201725D1 (de) 1995-04-20
NO305581B1 (no) 1999-06-28
DE69201725T2 (de) 1996-04-18
CZ282609B6 (cs) 1997-08-13
US6329354B1 (en) 2001-12-11
IE65963B1 (en) 1995-11-29
NZ241717A (en) 1997-02-24
AU1643392A (en) 1992-09-15
NO933044L (no) 1993-08-26
AU664368B2 (en) 1995-11-16
NO933044D0 (no) 1993-08-26
CA2101275C (en) 1998-08-04

Similar Documents

Publication Publication Date Title
DK0573604T3 (da) Fremgangsmåde til behandling af osteoporosis
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE69631134D1 (de) Verfahren zur bekämpfung infektiöser krankheiten unter verwendung dikationischer bis-benzimidazole
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ES2179473T3 (es) Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local.
NO942241L (da)
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE125706T1 (de) Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis.
EA199700183A1 (ru) Способ уменьшения риска невертебральных переломов костей
EP0515434A4 (en) Method for treating intestinal diseases
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE157010T1 (de) Amylin oder amylinanaloga enthaltende zusammensetzung, welche auch wahlweise insulin enthält, zur behandlung von anorexie und verwandten zuständen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE58456T1 (de) Zusammensetzung zur behandlung von laeuseplagen.
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression
ATE153859T1 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder
NO984198L (no) FremgangsmÕte for behandling av aggresjon
CO4410200A1 (es) Metodos para el tratamiento de osteoporosis usando fosfona- tos activos de huesos y hormonas paratiroidales
AR001226A1 (es) Métodos para el tratamiento de la osteoporosis utilizando fosofonatos activos y hormona paratiroidea